EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Performance evaluation of the Panbio COVID-19/Flu A&B Panel for detection of SARS-CoV-2, influenza A, and influenza B antigens using mid-turbinate nasal swabs

Shao-Hua Yu, Keun-Ju Kim, Chien-Chang Lee, Yanely Pineiro Puebla, Gelza Mae A Zabat, Hong-Mo Shih, Po-Ren Hsueh iD

Journal of Clinical Microbiology · 2024

DOI: 10.1128/jcm.00207-24 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, 2024. Verfasst von Shao-Hua Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human, Sensitivity and Specificity, Influenza B virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Panbio COVID-19/Flu A&B Panel (Abbott) is an in vitro diagnostic rapid test designed for the qualitative detection of nucleocapsid proteins SARS-CoV-2 and nucleoprotein influenza A and B antigens in nasal mid-turbinate (NMT) swab specimens from symptomatic individuals meeting COVID-19 and influenza clinical and/or epidemiological criteria. This study, the largest global one to date using fresh samples, aimed to assess the diagnostic sensitivity and specificity of the Panbio COVID-19/Flu A&B Panel in freshly collected NMT swab specimens from individuals suspected of respiratory viral infection consistent with COVID-19 and/or influenza within the first 5 days of symptom onset compared with results obtained with the cobas SARS-CoV-2 and influenza A/B qualitative assay (cobas 6800/8800 systems), which were tested using nasopharyngeal swab samples. A total of 512 evaluable subjects were enrolled in the COVID-19 cohort across 18 sites, and 1,148 evaluable subjects were enrolled in the influenza cohort across 22 sites in the Asia-Pacific, Europe, and the USA. The Panbio COVID-19/Flu A&B Panel demonstrated a sensitivity of 80.4% and a specificity of 99.7% for COVID-19. For influenza A, the sensitivity and specificity rates were 80.6% and 99.3%, respectively. Likewise, for influenza B, the sensitivity and specificity rates were 80.8% and 99.4%, respectively. In conclusion, the Panbio COVID-19/Flu A&B Panel emerges as a suitable rapid test for detecting COVID-19 and influenza in symptomatic subjects across diverse global populations, exhibiting high sensitivity. The assay achieved a sensitivity of 94.4% in samples with Ct ≤24 for COVID-19 and 92.6% in samples with Ct ≤30 for influenza A and B. IMPORTANCE The Panbio COVID-19/Flu A&B Panel is a suitable rapid test for detecting COVID-19 and influenza in symptomatic subjects across diverse global populations, exhibiting high sensitivity. The assay achieved a sensitivity of 94.0% in samples with Ct ≤24 for COVID-19 and 92.6% in samples with Ct ≤30 for influenza A and B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Influenza, HumanSensitivity and SpecificityInfluenza B virusSARS-CoV-2Antigens, ViralInfluenza A virusHumansAdultMiddle AgedFemaleMaleYoung AdultAdolescentAgedChildChild, PreschoolNasopharynxCOVID-19 TestingInfantAged, 80 and over

Stichwörter der Autor:innen

COVID-19Panbio COVID-19/Flu A&B PanelSARS-CoV-2cobas SARS-CoV-2 & Influenza A/B qualitative assaysensitivityspecificity

Substanzen

Antigens, Viral

Autor:innen und Institutionen

  • Department of Emergency Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Department of Laboratory Medicine, Korea University College of Medicine, Seoul, South Korea.
  • Department of Emergency Medicine, National Taiwan University, Taipei, Taiwan.
  • Palm Springs Community Health Center, Palm Springs, California, USA.
  • Health Cube Medical Clinics, Philippines, Philippines.
  • Department of Laboratory Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Po-Ren Hsueh

Zitieren

APA

Yu, S. H., Kim, K. J., Lee, C. C., Puebla, Y. P., Zabat, G. M. A., Shih, H. M., & Hsueh, P. R. (2024). Performance evaluation of the Panbio COVID-19/Flu A&B Panel for detection of SARS-CoV-2, influenza A, and influenza B antigens using mid-turbinate nasal swabs. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00207-24

Vancouver

Yu SH, Kim KJ, Lee CC, Puebla YP, Zabat GMA, Shih HM, et al. Performance evaluation of the Panbio COVID-19/Flu A&B Panel for detection of SARS-CoV-2, influenza A, and influenza B antigens using mid-turbinate nasal swabs. Journal of Clinical Microbiology. 2024. doi:10.1128/jcm.00207-24

BibTeX
@article{Yu2024,
  author = {Yu, Shao-Hua and Kim, Keun-Ju and Lee, Chien-Chang and Puebla, Yanely Pineiro and Zabat, Gelza Mae A and Shih, Hong-Mo and Hsueh, Po-Ren},
  title = {Performance evaluation of the Panbio COVID-19/Flu A&B Panel for detection of SARS-CoV-2, influenza A, and influenza B antigens using mid-turbinate nasal swabs},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  doi = {10.1128/jcm.00207-24}
}
Kostenlos starten →